Organization
Chongqing Precision Biotech Co., Ltd.
5 abstracts
Abstract
A novel co-receptor with mutated TIGIT to enhance PSCA CAR-T therapy for bladder cancer.Org: Chongqing Institute of Precision Medicine and Biotechnology Co, Ltd, Chongqing Precision Biotech Co., Ltd.,
Abstract
Phase I trial of hypoxia-responsive CEA CAR-T cell therapy in patients with heavily pretreated solid tumor via intraperitoneal or intravenous transfusion.Org: Chongqing Precision Biotech Co., Ltd.,
Abstract
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.Org: Chongqing Precision Biotech Co., Ltd., 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China,
Abstract
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.Org: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China, Chongqing Precision Biotech Co., Ltd., Chongqing, China,
Abstract
"Armed" CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer.Org: Chongqing Precision Biotech Co., Ltd.,